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Aim: To investigate trends in receipt and timing of antenatal corticosteroid (ACS) 
administration over a 10-year interval. 
Methods: Retrospective cohort study of all live births from 2006 to 2015 occurring at a 
Tertiary level teaching hospital in Adelaide, Australia. We analysed temporal trends in the 
receipt of single courses and repeat doses of ACSs, according to administration timing prior 
to birth. The main outcome measures were receipt of a single course of ACS and whether 
administration was ‘Optimal’ (≥24 hours to <7 days) or ‘Suboptimal’ (<24 hours OR ≥7 
days) according to timing prior to birth, as well as administration of repeat doses.  
Results: Among 47,105 live births, 4,191 (8.9%) received any ACS, while 1,009 (2.1%) 
received at least one repeat dose. From 2006/7 to 2014/15, receipt of a single course (RR 
1.33; 95%CI 1.21, 1.47) or repeat dose of ACS (RR 1.24; 95%CI 1.01, 1.55) increased. 
Among women giving birth between 23 to 34 weeks’ gestation, receipt of any ACS increased 
from 75% to 84%, while an optimally timed single course of ACS increased from 20.4% to 
31.0% (RR 1.40; 95%CI 1.24, 1.87). From 2006/7 to 2014/15, the greatest increase in ACS 
administration was evident among infants born 35-36 and ≥37 weeks’ gestation by caesarean 
section (RR 1.94; 95%CI 1.48, 2.55 and RR 2.55; 95%CI 1.86, 3.50, respectively).  
Conclusions: While frequently used, less than half of ACS administration prior to preterm 
birth was optimally timed. The impact of suboptimal ACS timing on neonatal outcomes 
requires further investigation. 
 
 







Administration of antenatal corticosteroids (ACS) to women at risk of preterm birth has been 
demonstrated to significantly reduce the risk of perinatal morbidities such as respiratory 
distress syndrome, intraventricular haemorrhage, and necrotising enterocolitis, as well as 
perinatal mortality.1, 2 Despite these benefits, significant challenges exist with respect to the 
optimal timing of administration of ACS prior to preterm birth. While the optimal ACS-to-
birth interval remains unclear, a notable reduction in efficacy is evident when the interval 
exceeds 7 days.2-4 However, only half the women who present with symptoms of preterm 
labour give birth within the subsequent 7 days.5-7 Conversely, some women will unexpectedly 
give birth in less than 24 hours, with administration of ACS in this setting still considered 
advantageous.8 Recent studies have demonstrated that while a large proportion of women 
receive ACS prior to preterm birth, suboptimal timing (administration <24 hours or ≥7 days 
prior to delivery) of such administration occurs in a majority.9, 10 Such difficulties in optimal 
timing of administration have led to investigations around the role of repeat ACS, for women 
who remain at risk of preterm birth 7-days or more following their initial course.11 While 
evidence has accumulated around the benefits of a repeat dose or doses of ACS on reducing 
the risk of respiratory distress syndrome and combined serious neonatal morbidity compared 
with a single course for women who remain at ongoing risk of preterm birth, uncertainty 
surrounds the potential long-term effects in both childhood and later life.11  
More recently, interest has grown in the potential benefits of ACS in reducing neonatal 
respiratory complications when administered to women at risk for later preterm birth12, as 
well as prior to elective caesarean section at term13. Despite such interest in the purported 




benefits, few attempts have been made to quantify patterns of ACS administration over time 
and according to factors such as timing, type of labour onset, and gestational age at delivery. 
Insight and understanding of these patterns are a first step towards optimal implementation of 
ACS in clinical practice. Therefore, we carried out a retrospective cohort study to investigate 




We performed a retrospective cohort study relating to all live births at the Women’s and 
Children’s Hospital in Adelaide, South Australia, Australia, between January 2006 and 
December 2015. The WCH is a specialist metropolitan tertiary level teaching hospital and 
South Australia’s largest maternity and obstetric service, with over 4,000 births each year. 
Data were obtained from the WCH Perinatal Statistics Collection (PSC), which includes 
information on maternal characteristics and prenatal, labour, delivery, and neonatal events for 
all live births, stillbirths and terminations of pregnancy of at least 400g birthweight or 20 
weeks’ gestation occurring at the hospital. Data are collected from each woman’s medical 
records after delivery by a specially trained research midwife utilising a standardised data 
collection form. In the case of women transferred from other hospitals, their corresponding 
medical history is also transferred and included in the review. A more detailed description of 
the electronic data collected can be found elsewhere.14, 15 Information stored within the PSC 
has previously been validated and shown to be reliable when compared with hospital case 
records16.  
 
Information collected on receipt of ACS included the timing of the first dose administered in 
relation to birth (none, < 24 hours, ≥ 24 hours to < 7 days, & ≥ 7 days), and the number of 




repeat doses administered. In accordance with guidelines in place at the hospital during the 
study period, a course of ACS consisted of 2 doses of 11.4mg betamethasone administered 24 
hours apart. Receipt of ACS were categorised as: 1) any administration of ACS prior to birth, 
irrespective of timing, 2), any administration of a repeat course of ACS prior to birth, 
irrespective of timing, 3) optimal administration of ACS (between 24 hours and 7 days prior 
to delivery), 3) suboptimal administration of ACS (less than 24 hours OR more than or equal 
to 7 days before birth). Gestational age at birth was taken from the perinatal record, which 
reflects the best clinical estimates according to information combined from last menstrual 
period and early ultrasonography.  
 
The prevalence of any and repeat ACS administration was evaluated according to various 
maternal and obstetric characteristics and compared using a generalised linear model 
(Poisson distribution) with robust variance estimates (and resulting relative risks (RR) and 
95% confidence intervals). The prevalence of any and repeat ACS administration was also 
evaluated according to each calendar time period, timing of ACS administration, individual 
categories of gestational age (<24, 24-27, 28-32, 33-34, 35-36, ≥37 weeks’ gestation), and 
type of labour onset (spontaneous labour, induction of labour, and LSCS without labour). 
Temporal trends of ACS administration over time were plotted using 3-year moving averages 
(2-year averages for the extremes). Statistical significance was defined as a 2-sided p <0.05. 
All statistical analyses were undertaken using STATA 11 (Stata, College Station, Texas). 
 
Ethics and governance approval was obtained from the Women’s and Children’s Health 
Network (HREC/14/WCHN/080).  
 
Results 





Among 47,105 women who had a live births between 2006 and 2015, 4,191 (8.9%) received 
any ACS, while 1,009 (2.1%) received at least one repeat dose.  
 
Temporal trends from 2006 to 2015 in the frequency of receipt of any ACS (single or repeat) 
and repeat ACS administration are displayed in Figures 1A and 1B. Rates of ACS 
administration increased significantly between 2006/7 and 2014/15, from 7.2/100 to 9.6/100 
(RR 1.33; 95%CI 1.21, 1.47). Similarly, the rate of women receiving any repeat dose of ACS 
increased from 1.5/100 to a peak of 2.9/100 (RR 1.87; 95%CI 1.53, 2.29) in 2012/13, before 
dropping to 1.9/100 (RR 1.24; 95%CI 1.01, 1.55) in 2014/15. The proportion of women 
receiving multiple repeat doses increased substantially from 2006 to 2013, before dropping 
back to the rates reported in 2006/7 (16%, 2006/7; 30%, 2008/9; 48%, 2010/11; 51%, 
2012/13; 19%, 2014/15). When examined according to gestational age at birth, significant 
increases in any ACS administration were only evident among infants born ≥33 weeks’ 
gestation (Figure 1A). Administration of ACS to women delivering beyond 35 week’s 
gestation accounted for 35% and 50% of overall ACS use in 2006/7 and 2014/15 
respectively.  
 
Temporal trends from 2006 to 2015 in the timing of receipt of ACS prior to birth are 
displayed in Figures 2A and 2B. Regardless of gestation at birth, administration of a single 
course of ACS with optimal timing prior to birth significantly increased over the 10-year 
period. Among infants born 23-34 weeks’ gestation, receipt of any ACS increased from 75% 
to 84% (RR 1.12; 95%CI 1.05, 1.18) between 2006/7 and 2014/15, while those receiving 
optimally timed ACS increased from 20% to 31% after single course (RR 1. 50; 95%CI 1.24, 
1.87). If extended to include any ACS administration that occurred from 0 to 7 days prior to 




birth, this increased from 44% to 51% (RR 1.16; 95%CI 1.02, 1.31) between 2006/7 and 
2014/15. 
 
Temporal trends from 2006 to 2015 in timing of ACS administration according to labour 
onset are displayed in Figure 3A. According to onset of labour, administration of any ACS 
increased between 2006/7 and 2014/15 among mothers delivering following spontaneous 
onset labour (72% vs. 79%; RR 1.10; 95%CI 1.01, 1.21), LSCS (no labour) (80% vs. 90%; 
RR 1.13: 95%CI 1.04, 1.21), and induction of labour (77% vs. 85%; RR 1.10: 95%CI 0.91, 
1.34). From 2006 to 2015, approximately half of the women who received an initial course of 
ACS more than 7 days prior to birth, but still ended up delivering prior to 35 weeks, ended up 
receiving a repeat dose (58%). Among these women, when separated according to type of 
labour onset, the proportion of women receiving a repeat dose of ACS was 57%, 47%, and 
63% according to spontaneous labour onset, induction of labour, and LSCS respectively.  
 
Among infants born 35 to 36 weeks’ gestation, receipt of any ACS increased from 19.3% to 
34.6% between 2006/7 and 2014/15. Of the group receiving ACS, optimal timing of a single 
course increased from 22.7% to 45.6% (RR 2.01, 95%CI 1.35, 2.99). According to onset of 
labour, any administration of ACS significantly increased among women delivering 
following LSCS (no labour) (39% vs 76%; RR 1.94, 95%CI 1.48, 2.55), but not following 
spontaneous onset labour (13.8% vs 16.2%; RR 1.17, 95%CI 0.78, 1.75) or induction of 
labour (17.6% vs 26.1%; RR 1.49, 95%CI 0.95, 2.32) (Figure 3B). 
 
From 2006/7 to 2014/15, a significant increase in ACS administration was evident among 
infants born ≥37 weeks’ gestation by LSCS (without labour) (4.9% vs. 12.5%; RR 2.55, 
95%CI 1.86, 3.50). No such differences were evident among those who delivered following 




spontaneous onset labour (0.9% vs. 1.0%; RR 1.01, 95%CI 0.66, 1.56) or induction of labour 
(1.8% vs. 1.5%; RR 0.80, 95%CI 0.53, 1.21).  
 
Administration of any ACS was significantly higher among women who were of low 
socioeconomic status, advanced maternal age (35 years or greater), smokers (including those 
who quit smoking during pregnancy), multiparous, and overweight or obese (Supplemental 
Table 1). Obstetric characteristics such as previous obstetric history of preterm birth, preterm 
pre-labour rupture of membranes, plurality, pre-existing diabetes, cervical suture, threatened 
preterm labour, and antepartum haemorrhage were all associated with more than a 2-fold 
increased risk of receiving at least a single course of ACS during pregnancy (Supplemental 
Table 2).   
 
When restricted to births occurring less than 35 weeks’ gestation, despite high rates of overall 
ACS use, the presence of obstetric characteristics such as gestational diabetes, threatened 
miscarriage, or threatened preterm labour were all associated with a 21-39% less likelihood 
of optimally timed ACS administration (Table 1). In contrast, pre-eclampsia, suspected 
IUGR, iatrogenic preterm birth, induction of labour, and increasing calendar year were all 
associated with 37-67% increased likelihoods of optimally timed ACS administration. Non-
medical maternal characteristics were not associated with optimally timed ACS 
administration (Supplemental Table 3).  
 
Discussion 
Despite significant improvements in the overall use of ACS over the 10-year period, optimal 
timing of a single course prior to preterm birth does not occur in the majority of cases. Use of 
repeat ACS administration has increased over time among women delivering prior to 35 




weeks’ gestation, with a shift away from multiple repeat ACS doses towards a single repeat 
ACS dose as required.  
 
Previous studies have reported variable ACS administration rates of among live births below 
35 weeks’ gestation of between 35% to 93%.7, 17-19 While not always clear as to whether such 
administration relates to a partial or complete single course of ACS as evaluated in this study, 
studies reporting optimal administration have uniformly demonstrated low rates of 25% to 
50% of livebirths,9, 10, 20 More recently, interest has grown in determining what defines 
optimal ACS administration. While often regarded and studied as administration occurring 
more than 24 hours but less than 7 days following the first dose, there is still evidence that 
ACS use reduces neonatal death even when birth occurs within 24 hours of the first dose.2, 4 
Therefore, whether anticipated or not, there is advantage in ACS administration within the 
first 24 hours, albeit full benefits with respect to prevention of neonatal respiratory 
complications do not become evident until beyond the 24 hour ACS-to-birth interval.8 
However, even if ACS administration less than 24 hour prior to birth was considered optimal, 
overall optimal timing of ACS administration remained less than 50% in this cohort.   
 
The prevalence of optimal timing of ACS administration differed substantially according to 
maternal obstetric history, being lowest among women with a history of threatened 
miscarriage, threatened preterm labour, and gestational diabetes, while highest among women 
with suspected IUGR and pre-clampsia. These differences may reflect clinical heterogeneity 
related to different indicated and spontaneous preterm birth pathways. It is positive that 
iatrogenic preterm birth was associated with the highest rates of optimal ACS timing, but this 
still achieved in less than half of women. Such findings are in agreement with previous 
studies,9 but raise questions as to what degree optimal administration rates can be improved. 




The unpredictable occurrence and varying clinical courses with regard to when delivery 
occurs spontaneously or is medically indicated across various obstetric complications make 
optimal ACS administration a challenge, with future investigations needed to better  
determine optimal steroid administration strategies. 
 
Despite the noted benefits of administration between 34 to 35 weeks’ gestation, we identified 
a much lower rate of ACS administration at this gestation compared with less than 34 weeks’ 
gestation (88% vs. 70%, respectively). This finding is consistent with that of other studies 
where the absolute difference in ACS rates at these gestations differed by 20-40%.10, 19, and 
highlights a key area for improving clinical practice and the continued promotion of clinical 
practice guidelines.  
 
Limited studies have examined trends in the administration of repeat doses of ACS. Similar 
to our findings, Levin et al. demonstrated an increase in the use of repeat doses from 2006 to 
2011,9 however, in contrast to their findings of a consistent increase in use over time, our 
findings demonstrated a decline in use in more recent years. We also observed a decline in 
the number of total repeat doses administered. Independently of repeat doses we saw 
significant increases in the optimal administration of ACS. Among women who received a 
course of ACS more than 7 days prior to birth, but still ended up delivering prior to 35 weeks, 
53% of them ended up receiving a repeat ACS dose, compared to rates of 60% and 70% in 
two recent studies.9, 21 Notably, a recent study demonstrated no difference in the optimal 
timing of ACS prior to birth following the introduction of a rescue course (i.e. repeat ACS 
dose) protocol20, so there remains a need for improvement with respect to the prediction of 
preterm birth and subsequent timing of ACS administration.    
 




Despite scant literature on the usage pattern of ACS beyond 35 weeks’ gestation, our 
identified rates of ACS administration among women delivering between 35-36 weeks’ 
gestation (34.6%) and more than 37 weeks’ gestation (2.9%) are much higher than that 
reported in a recent population based study from Canada (11% and 1.2% respectively).10 
While Razaz et al.10 did not stratify usage patterns according to method of delivery, we 
observed a significant increase in ACS prior to elective caesarean section, occurring between 
37 and 38 weeks’ gestation, from 8.8% in 2006/7 to 21.8% in 2014/15. Such an increase 
mirrors the updated publication of clinical guidelines by the Royal College of Obstetricians 
and Gynaecologists (RCOG) in 2010 strongly recommending use of ACS prior to planned 
elective caesarean section.22 
 
A strength of this study lies in the large sample size and the rich and validated data capture on 
a large range of maternal and obstetric characteristics. An additional strength lies in the 
presence of data on receipt of a repeat dose of ACS, which has been missing in a number of 
previous studies,10 and the stratification of outcomes according to type of labour onset. 
 
Limitations include the lack of data on the exact gestational age of administration of ACS, 
rather just timing of administration. In addition, timing of administration relates to timing of 
birth following the first course, rather than timing of birth following any repeat doses. The 
exact type of ACS administered is not recorded and could either be betamethasone or 
dexamethasone, although betamethasone was listed as the preferred option in hospital clinical 
guidelines and is likely to represent the vast majority of use. Further, no data were available 
on indication for ACS use.  
 




In conclusion, although there were significant improvements in the use of ACS over the 10-
year period, optimal timing of a single course prior to preterm birth occurred in less than 50% 
of cases. Despite an initial increase in the use of repeat doses of ACS, there has been a 
decline in both the administration of a repeat dose and the number of repeat doses in more 
recent years, potentially relating to concerns about long-term effects on child development. 
The greatest increases in optimally timed ACS use were evident among planned deliveries 
occurring between 35 and 36 weeks’ gestation and beyond 37 weeks’ gestation, now 
accounting for 50% of overall ACS use.  
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Table 1. Receipt of a single course of optimally timed antenatal corticosteroids according to 
obstetric characteristics among 2,926 live births occurring between 23 and 34 weeks’ 
gestation, 2006-2015 
Figure 1. Temporal trends in the administration of any antenatal corticosteroids (A) or a 
repeat dose of antenatal corticosteroids (B) according to gestational age at delivery, Adelaide, 
2006-2015.   
Figure 2. Temporal trends in the timing of a single course of ACS and a repeat dose of ACS 
among deliveries occurring between 23 and 34 weeks gestation (A) and between 35 and 36 
weeks’ gestation (B), Adelaide, 2006-2015. Data points are cumulative percentages and 
represent 3-year moving averages (2-year averages for the extremes).  
Figure 3. Temporal trends in the optimal and suboptimal timing of a single course of ACS 
according to labour onset among deliveries occurring between 23 and 34 weeks’ gestation 
(A) and between 35 and 36 weeks’ gestation (B), Adelaide, 2006-2015.  
Supplemental Table 1. Number of Live Births and Rate of Any and Repeat Antenatal 
Corticosteroid Administration by Maternal Characteristics Among 47,105 Live Births 
Between 2006 and 2015 
Supplemental Table 2. Rate of Any and Repeat Antenatal Corticosteroid Administration by 
Obstetric Characteristics Among 47,105 Live Births Between 2006 and 2015 
Supplemental Table 3. Receipt of a single course of optimally timed antenatal 
corticosteroids according to maternal characteristics among 2,926 live births occurring 
between 23 and 34 weeks’ gestation, 2006-2015 
  




Table 1. Receipt of a single course of optimally timed antenatal corticosteroids according to obstetric 
characteristics among 2,926 live births occurring between 23 and 34 weeks’ gestation, 2006-2015 
 All Live Births Optimal Timing‡ of ACS Administration 
Obstetric Characteristic n % n Rate/100 RR (95% CI) 
Plurality      
Singleton 2369 81.0 656 27.7 Reference 
Twins 518 17.7 128 24.7 0.89 (0.76, 1.05) 
Triplets or more 39 1.3 11 28.2 1.02 (0.61, 1.70) 
Previous Obstetric History of Preterm Birth      
No 1128 38.6 313 27.8 Reference 
Yes 433 14.8 101 23.3 0.84 (0.69, 1.02) 
Not Applicable 1365 46.7 - - - 
Gestational Diabetes      
No 2655 90.7 736 27.7 Reference 
Yes 271 9.3 59 21.8 0.79 (0.62, 0.99) 
Hypertensive Disorders of Pregnancy      
None 2406 82.2 596 24.8 Reference 
Gestational Hypertension 36 1.2 10 27.8 1.12 (0.66. 1.91) 
Pre-Eclampsia 484 16.5 189 39.1 1.58 (1.38, 1.80) 
Cervical Suture      
No 2817 96.3 771 27.4 Reference 
Yes 109 3.7 24 22.0 0.80 (0.56, 1.16) 
Threatened Miscarriage      
No 2843 97.2 781 27.5 Reference 
Yes 82 2.8 14 16.9 0.61 (0.38, 0.99) 
Threatened Preterm Labour      
No 1223 41.8 414 33.9 Reference 
Yes 1703 58.2 381 22.4 0.66 (0.59, 0.74) 
Antepartum Haemorrhage      
No 2424 82.8 663 27.4 Reference 
Yes 502 17.2 132 26.3 0.96 (0.82, 1.13) 
Suspected IUGR      




No 2359 80.6 598 25.4 Reference 
Yes 567 19.4 197 34.7 1.37 (1.20, 1.57) 
Preterm Pre-labour Rupture of Membranes      
No 1678 57.4 467 27.8 Reference 
Yes 1248 42.7 328 26.3 0.94 (0.84, 1.07) 
Delivery      
Spontaneous Vaginal 1273 43.5 313 24.6 Reference 
LSCS, in labour 621 21.2 146 23.5 0.96 (0.80, 1.14) 
LSCS, no labour 1032 35.3 336 32.6 1.32 (1.16, 1.51) 
Labour Onset      
Spontaneous 1618 55.3 357 22.1 Reference 
No Labour (Elective LSCS) 1032 35.3 336 32.6 1.48 (1.30, 1.68) 
Induction 276 9.4 102 37.0 1.67 (1.40, 2.00) 
Type of preterm birth      
Spontaneous 1618 55.3 357 22.1 Reference 
Medically Indicated 1308 44.7 438 33.5 1.52 (1.35, 1.71) 
Year of Delivery      
2006-2007 570 19.5 116 20.4 Reference 
2008-2009 587 20.1 150 25.6 1.26 (1.01, 1.55) 
2010-2011 588 20.1 179 30.4 1.50 (1.22, 1.83) 
2012-2013 652 22.3 186 28.5 1.40 (1.15, 1.72) 
2014-2015 529 18.1 164 31.0 1.52 (1.24, 1.87) 
Abbreviations: ACS, antenatal corticosteroid; RR, relative risk; CI, confidence interval; LSCS, lower segment caesarean 
section 










Figure 1. Temporal trends in the administration of any antenatal corticosteroids (A) or a 
repeat dose of antenatal corticosteroids (B) according to gestational age at delivery, Adelaide, 
2006-2015.   
 





Figure 2. Temporal trends in the timing of a single course of ACS and a repeat dose of ACS 
among deliveries occurring between 23 and 34 weeks gestation (A) and between 35 and 36 
weeks’ gestation (B), Adelaide, 2006-2015. Data points are cumulative percentages and 
represent 3-year moving averages (2-year averages for the extremes).  
 





Figure 3. Temporal trends in the optimal and suboptimal timing of a single course of ACS 
according to labour onset among deliveries occurring between 23 and 34 weeks’ gestation 
(A) and between 35 and 36 weeks’ gestation (B), Adelaide, 2006-2015.  
  





Supplemental Table 1. Number of Live Births and Rate of Any and Repeat Antenatal Corticosteroid 
Administration by Maternal Characteristics Among 47,105 Live Births Between 2006 and 2015 
 All Live 
Births 
Any Antenatal Corticosteroid 
Administration 




n %† n Rate/100 RR (95% CI) n Rate/100 RR (95% CI) 
Age         
<20 1719 3.7 204 11.9 1.41 (1.22,1.63) 41 2.4 1.26 (0.91,1.74) 
20-24 7011 14.9 614 8.8 1.04 (0.95,1.14) 138 2.0 1.04 (0.85,1.27) 
25-29 13715 29.1 1154 8.4 Ref 260 1.9 Ref 
30-34 14792 31.4 1202 8.1 0.97 (0.89,1.04) 292 2.0 1.04 (0.88,1.23) 
35 9868 21.0 1020 10.3 1.23 (1.13,1.33) 278 2.8 1.49 (1.26,1.76) 
Missing 0 - - - - - - - 
Parity         
0 21086 44.9 1723 8.2 1.01 (0.94,1.08) 379 1.8 0.88 (0.76,1.02) 
1 15384 32.7 1244 8.1 Ref 313 2.0 Ref 
2 6371 13.6 675 10.6 1.31 (1.20,1.43) 175 2.8 1.35 (1.12,1.62) 
3 or more 4170 8.9 539 12.9 1.60 (1.45,1.76) 140 3.3 1.65 (1.35,2.01) 
Missing 94 - - - - - - - 
Ethnicity         
Caucasian 30460 64.7 3118 10.2 Ref 760 2.5 Ref 
Aboriginal and/or 
TSI 
1847 3.9 326 
17.7 
1.72 (1.55,1.92) 68 
3.7 
1.48 (1.16,1.88) 
Asian 10436 22.2 530 5.1 0.50 (0.45,0.54) 116 1.1 0.45 (0.37,0.54) 
Other 4361 9.3 219 5.0 0.49 (0.43,0.56) 65 1.5 0.60 (0.46,0.77) 
Missing 1 - - - - - - - 
Body Mass Index, 
kg/m2 





<18.5 1360 3.5 100 7.4 1.29 (1.05,1.58) 21 1.5 1.13 (0.73,1.76) 
18.5-24.9 19754 51.1 1128 5.7 Ref 269 1.4 Ref 
25.0-29.9 9758 25.2 636 6.5 1.14 (1.04,1.26) 149 1.5 1.12 (0.92,1.37) 




≥30 7782 20.1 750 9.6 1.69 (1.54,1.85) 177 2.3 1.67 (1.38,2.02) 
Missing 8451 - - - - - - - 
Socioeconomic Status         
5 (Highest) 8283 17.6 638 7.7 0.65 (0.59,0.72) 157 1.9 0.66 (0.55,0.81) 
4 10858 23.1 920 8.5 0.72 (0.66,0.78) 216 2.0 0.70 (0.58,0.83) 
3 9899 21.1 647 6.5 0.55 (0.50,0.61) 152 1.5 0.54 (0.44,0.65) 
2 7670 16.3 758 9.9 0.84 (0.77,0.91) 186 2.4 0.85 (0.71,1.02) 
1 (Lowest) 10316 21.9 1219 11.8 Ref 295 2.9 Ref 
Missing 79 - - - - - - - 
Smoking         
Non-Smoker 38640 83.8 2967 7.7 Ref 726 1.9 Ref 
Quit Smoking 1705 3.7 154 9.0 1.18 (1.01,1.37) 30 1.8 0.94 (0.65,1.35) 
Current Smoker 5767 12.5 776 13.5 1.75 (1.62,1.89) 175 3.0 1.62 (1.37,1.90) 
Missing 4062 - - - - - - - 
Pre-existing Diabetes         
No 46629 99.0 4079 8.8 Ref 986 2.1 Ref 
Yes 476 1.0 115 24.2 2.76 (2.32,3.28) 23 4.8 2.29 (1.53,3.40) 
Missing 0 - - - - - - - 
Abbreviations: RR, relative risk; CI, confidence interval 
† Percentages are calculated from non-missing values 
 
  




Supplemental Table 2. Rate of Any and Repeat Antenatal Corticosteroid Administration by Obstetric 
Characteristics Among 47,105 Live Births Between 2006 and 2015 
 All Live 
Births 
Any Antenatal Corticosteroid 
Administration 




n %† n Rate/100 RR (95% CI) n Rate/100 RR (95% CI) 
Plurality         
Singleton 45864 97.4 3526 7.7 Ref 828 1.8 Ref 
Twins 1199 2.6 631 52.6 6.85 (6.42, 7.29) 165 13.8 7.62 (6.51, 8.92) 








Missing 0 - - - - - - - 
Previous Obstetric 
History of Preterm 
Birth 





No 23736 50.4 1867 7.9 Ref 461 1.9 Ref 
Yes 2283 4.9 604 26.5 3.36 (3.09, 3.66) 169 7.4 3.81 (3.21, 4.52) 
Not Applicable 21086 44.8 - - - - - - 
Missing 0 - - - - - - - 
Gestational Diabetes         
No 42855 91.0 3754 8.8 Ref 887 2.1 Ref 
Yes 4250 9.0 440 10.4 1.18 (1.07, 1.30) 122 2.9 1.39 (1.15, 1.68) 
Missing 0 - - - - - - - 
Cervical Suture         
No 46866 99.5 4060 8.7 Ref 962 2.1 Ref 
Yes 239 0.5 134 56.1 6.47 (5.74, 7.30) 47 19.7 9.58 (7.44, 12.34) 
Missing 0 - - - - - - - 
Threatened 
Miscarriage 





No 46423 98.6 4077 8.8 Ref 974 2.1 Ref 
Yes 682 1.4 117 17.2 1.95 (1.65, 2.31) 35 5.1 2.45 (1.76, 3.40) 
Missing 0 - - - - - - - 











No 43779 92.9 2569 5.9 Ref 637 1.5 Ref 
Yes 3326 7.1 1625 48.9 8.33 (7.90, 8.77) 372 11.2 7.69 (6.80, 8.69) 
Missing 0 - - - - - - - 
Antepartum 
Haemorrhage 





No 45530 96.7 3551 7.8 Ref 815 1.8 Ref 
Yes 1575 3.3 643 40.8 5.23 (4.89, 5.60) 194 12.3 6.88 (5.93, 7.98) 









No 44646 94.8 2994 6.7 Ref 711 1.6 Ref 
Yes 2459 5.2 1200 48.8 7.28 (6.89, 7.68) 298 12.1 7.61 (6.68, 8.67) 
Missing 0 - - - - - - - 
Delivery         
Vaginal 33125 70.3 1593 4.8 Ref 319 1.0 Re 
LSCS, in labour 6765 14.4 740 10.9 2.27 (2.09, 2.47) 190 2.8 2.92 (2.44, 3.49) 
LSCS, no labour 7215 15.3 1861 25.8 5.36 (5.03, 5.72) 500 6.9 7.20 (6.26, 8.28) 
Missing 0 - - - - - - - 
Labour Onset         
Spontaneous 24960 53.0 1660 6.7 Ref 353 1.4 Ref 
No Labour (Elective 
LSCS) 
7215 15.3 1861 
25.8 
3.88 (3.64, 4.13) 500 
6.9 
4.90 (4.28, 5.61) 
Induction 14930 31.7 673 4.5 0.68 (0.62, 0.74) 156 1.0 0.74 (0.61, 0.89) 
Missing 0 - - - - - - - 
Type of preterm birth         
Spontaneous 3001 52.4 1449 48.3 Ref 307 10.2 Ref 
Medically Indicated 2725 47.6 1691 62.1 1.29 (1.23, 1.35) 468 17.2 1.68 (1.47, 1.92) 
Not Applicable 41379 - - - - - - - 
Missing 0 - - - - - - - 
Year of Delivery         




2006-2007 9222 19.6 664 7.2 Ref 142 1.5 Ref 
2008-2009 9582 20.3 811 8.5 1.18 (1.07, 1.30) 244 2.6 1.65 (1.35, 2.03) 
2010-2011 9516 20.2 875 9.2 1.28 (1.16, 1.41) 171 1.8 1.17 (0.94, 1.45) 
2012-2013 9585 20.4 962 10.0 1.39 (1.27, 1.53) 276 2.9 1.87 (1.53, 2.29) 
2014-2015 9200 19.5 882 9.6 1.33 (1.21, 1.47) 176 1.9 1.24 (1.01, 1.55) 
Missing 0 - - - - - - - 
Abbreviations: RR, relative risk; CI, confidence interval; LSCS, lower segment caesarean section 
† Percentages are calculated from non-missing data 
 
  




Supplemental Table 3. Receipt of a single course of optimally timed antenatal corticosteroids according to 
maternal characteristics among 2,926 live births occurring between 23 and 34 weeks’ gestation, 2006-2015 
 All Live Births Optimal Timing‡ of ACS Administration 
Maternal Characteristic n %† n Rate/100 RR (95% CI) 
Age      
<20 162 5.5 52 32.1 1.15 (0.89, 1.47) 
20-24 421 14.4 115 27.3 0.97 (0.81, 1.18) 
25-29 835 28.5 234 28.0 Reference 
30-34 839 28.7 216 25.7 0.92 (0.78, 1.08) 
35 669 22.9 178 26.6 0.95 (0.80, 1.12) 
Missing 0 - - - - 
Parity      
0 1365 46.8 381 27.9 1.04 (0.90, 1.20) 
1 796 27.3 214 26.9 Reference 
2 409 14.0 110 26.9 1.00 (0.82, 1.22) 
3 or more 344 11.8 85 24.7 0.92 (0.74, 1.14) 
Missing 12 - - - - 
Ethnicity      
Caucasian 2219 75.9 583 26.3 Reference 
Aboriginal and/or TSI 231 7.9 84 36.4 1.38 (1.15, 1.67) 
Asian 329 11.3 87 26.4 1.01 (0.83, 1.23) 
Other 146 5.0 41 28.1 1.07 (0.82, 1.40) 
Missing 1 - - - - 
Body Mass Index, kg/m2      
<18.5 60 3.7 14 23.3 0.83 (0.52, 1.33) 
18.5-24.9 715 44.1 201 28.1 Reference 
25.0-29.9 415 25.6 127 30.6 1.09 (0.90, 1.31) 
≥30 433 26.7 135 31.2 1.11 (0.92, 1.33) 
Missing 1303 - - - - 
Socioeconomic Status      
5 (Highest) 455 15.6 102 22.4 0.78 (0.64, 0.95) 
4 611 21.0 164 26.8 0.93 (0.79, 1.11) 




3 467 16.0 129 27.6 0.96 (0.80, 1.15) 
2 485 16.7 140 28.9 1.01 (0.84, 1.20) 
1 (Lowest) 895 30.7 257 28.7 Reference 
Missing 13 - - - - 
Smoking      
Non-Smoker 1974 74.6 531 26.9 Reference 
Quit Smoking 100 3.8 38 38.0 1.41 (1.09, 1.83) 
Current Smoker 572 21.6 170 29.7 1.10 (0.96, 1.28) 
Missing 280 - - - - 
Pre-existing Diabetes      
No 2837 97.0 770 27.1 Reference 
Yes 89 3.0 25 28.1 1.03 (0.75, 1.43) 
Missing 0 - - - - 
Abbreviations: ACS, antenatal corticosteroid; RR, relative risk; CI, confidence interval 
‡ Optimal ACS administration defined as administration of the first single course of ACS  >24 hours but <7 days prior to 
delivery 
† Percentages are calculated from non-missing data 
 
 
 
